PROTEASOME DYSFUNCTION A KEY PATHOLOGIC FEATURE OF ALZHEIMER’S DISEASE MITIGATED BY PROTEASOME ACTIVATORS
Andrew Pickering · 2024
Read PROTEASOME DYSFUNCTION A KEY PATHOLOGIC FEATURE OF ALZHEIMER’S DISEASE MITIGATED BY PROTEASOME ACTIVATORS by Andrew Pickering (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11692773.txt.
Description
Andrew Pickering argues in a 2024 study that a broken protein-disposal system sits at the heart of Alzheimer's disease. The disease is the top cause of dementia, and many drug trials aimed at the amyloid protein have failed. Pickering's team tested whether amyloid harms the proteasome, the cell machine that chews up worn-out proteins.
In lab cells, clumps of amyloid slowed one form of the proteasome and broke apart the larger form. Drugs that boost the machine cut the harm. In fruit flies and mice that make amyloid, the same drugs delayed death, protected memory, and improved learning. The findings suggest that raising proteasome activity could become a new way to treat the disease.
Catalog record
| CREATOR | Andrew Pickering |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |